These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7531732)

  • 1. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge.
    Ciprandi G; Buscaglia S; Pesce G; Passalacqua G; Rihoux JP; Bagnasco M; Canonica GW
    J Allergy Clin Immunol; 1995 Feb; 95(2):612-21. PubMed ID: 7531732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deflazacort protects against late-phase but not early-phase reactions induced by the allergen-specific conjunctival provocation test.
    Ciprandi G; Buscaglia S; Pesce GP; Iudice A; Bagnasco M; Canonica GW
    Allergy; 1993 Aug; 48(6):421-30. PubMed ID: 7902021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity.
    Ciprandi G; Buscaglia S; Catrullo A; Pesce G; Fiorino N; Montagna P; Bagnasco M; Canonica GW
    Clin Exp Allergy; 1997 Feb; 27(2):182-91. PubMed ID: 9061218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical ocular levocabastine reduces ICAM-1 expression on epithelial cells both in vivo and in vitro.
    Buscaglia S; Paolieri F; Catrullo A; Fiorino N; Riccio AM; Pesce G; Montagna P; Bagnasco M; Ciprandi G; Canonica GW
    Clin Exp Allergy; 1996 Oct; 26(10):1188-96. PubMed ID: 8911706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge.
    Ciprandi G; Buscaglia S; Pronzato C; Benvenuti C; Cavalli E; Bruzzone F; Canonica GW
    Ann Allergy Asthma Immunol; 1995 Nov; 75(5):446-52. PubMed ID: 7583868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allergic subjects express intercellular adhesion molecule--1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge.
    Ciprandi G; Buscaglia S; Pesce G; Villaggio B; Bagnasco M; Canonica GW
    J Allergy Clin Immunol; 1993 Mar; 91(3):783-92. PubMed ID: 8095941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of deflazacort on allergen-specific conjunctival challenge.
    Ciprandi G; Buscaglia S; Iudice A; Pesce GP; Bagnasco M; Canonica GW
    Eur J Clin Pharmacol; 1993; 45 Suppl 1():S35-41. PubMed ID: 8313933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiallergic activity of topical lodoxamide on in vivo and in vitro models.
    Ciprandi G; Buscaglia S; Catrullo A; Paolieri F; Riccio AM; Fiorino N; Canonica GW
    Allergy; 1996 Dec; 51(12):946-51. PubMed ID: 9020426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergen-specific challenge induces intercellular adhesion molecule 1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects. Relationships with early and late inflammatory phenomena.
    Ciprandi G; Pronzato C; Ricca V; Passalacqua G; Bagnasco M; Canonica GW
    Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1653-9. PubMed ID: 7524984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions.
    Ciprandi G; Cosentino C; Milanese M; Tosca MA
    Ann Allergy Asthma Immunol; 2003 Apr; 90(4):434-8. PubMed ID: 12722967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma.
    Fasce L; Ciprandi G; Pronzato C; Cozzani S; Tosca MA; Grimaldi I; Canonica GW
    Int Arch Allergy Immunol; 1996 Mar; 109(3):272-6. PubMed ID: 8620097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis.
    Day JH; Briscoe MP; Rafeiro E; Hewlett D; Chapman D; Kramer B
    Allergy Asthma Proc; 2004; 25(1):59-68. PubMed ID: 15055564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terfenadine exerts antiallergic activity reducing ICAM-1 expression on nasal epithelial cells in patients with pollen allergy.
    Ciprandi G; Pronzato C; Ricca V; Varese P; Del Giacco GS; Canonica GW
    Clin Exp Allergy; 1995 Sep; 25(9):871-8. PubMed ID: 8564726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity.
    Ciprandi G; Tosca M; Ricca V; Passalacqua G; Riccio AM; Bagnasco M; Canonica GW
    Clin Exp Allergy; 1997 Oct; 27(10):1160-6. PubMed ID: 9383256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cetirizine in a conjunctival provocation test with allergens.
    Schoeneich M; Pécoud AR
    Clin Exp Allergy; 1990 Mar; 20(2):171-4. PubMed ID: 1972648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression.
    Ciprandi G; Pronzato C; Ricca V; Passalacqua G; Danzig M; Canonica GW
    Clin Exp Allergy; 1997 Oct; 27(10):1175-83. PubMed ID: 9383258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit.
    Day JH; Briscoe M; Widlitz MD
    J Allergy Clin Immunol; 1998 May; 101(5):638-45. PubMed ID: 9600501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal fluticasone propionate reduces ICAM-1 on nasal epithelial cells both during early and late phase after allergen challenge.
    Ciprandi G; Ricca V; Passalacqua G; Fasolo A; Canonica GW
    Clin Exp Allergy; 1998 Mar; 28(3):293-9. PubMed ID: 9543078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of different doses of terfenadine on the conjunctival provocation test.
    Ciprandi G; Buscaglia S; Iudice A; Canonica GW
    Allergy; 1992 Aug; 47(4 Pt 1):309-12. PubMed ID: 1443450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.